New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
Key Highlights
- ➤SKYRIZI achieved higher clinical remission and endoscopic response versus placebo at Week 12
- ➤SKYRIZI sustained clinical and endoscopic outcomes through 144 weeks in Crohn's disease
- ➤74.5% of fistulizing Crohn's patients achieved no draining fistulas after five years
- ➤RINVOQ real-world data showed 57% clinical remission at six months in isolated ileal Crohn's
- ➤RINVOQ achieved 93.3% clinical remission among fistulizing patients remaining on treatment
Expert Statements
Ryan DeMasi, M.D., vice president, global medical affairs, immunology, AbbVie
“People living with IBD want treatments that meaningfully reduce the burden of their disease.”
Ryan DeMasi, M.D., vice president, global medical affairs, immunology, AbbVie
“Our presence at ACG reflects AbbVie’s drive, as a leader in IBD, to provide what matters most to patients — therapies that perform over time and against the most complicated drivers of disease.”
New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease PR Newswire
* New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints and observed subgroups * New open-label extension analyses demonstrate sustained endoscopic outcomes over time with SKYRIZI, even in patients with complex disease characteristics and prior treatment exposure * In real-world studies, patients with advanced Crohn's disease achieved disease control with RINVOQ, highlighting its potential benefit for difficult-to-treat patients * The breadth of scientific abstracts and oral presentations at the American College of Gastroenterology 2026 Annual Scientific Meeting demonstrates AbbVie's pursuit to address the complexities of inflammatory bowel disease care NORTH CHICAGO, Ill., Oct. 11, 2026 /PRNewswire/ -- AbbVie today announced the presentation of 22 scientific abstracts from its market-leading inflammatory bowel disease (IBD) portfolio at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Tennessee, Oct. 9-14. Data presented will include newly unveiled AFFIRM results showing efficacy for SKYRIZI(®) (risankizumab-rzaa) in advanced therapy-naïve Crohn's disease (CD) patients, open-label extension analyses demonstrating long-term outcomes with SKYRIZI in difficult-to-treat IBD and growing real-world evidence supporting RINVOQ(®) (upadacitinib) in advanced CD.
Get started
Create a free account to read the full story.